A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Shanghai Henlius Biotech
- 29 Nov 2018 Status changed from active, no longer recruiting to completed, according to the Shanghai Henlius Biotech media release.
- 29 Nov 2018 According to a Shanghai Henlius Biotech media release, the company has completed data analysis of this trial.
- 04 Dec 2017 New trial record